SomaLogic

Understanding the complexity of biology with SOMAscan-based highly multiplexed protein measurements : application to cardiovascular diseases

Nicolas Autret, PhD
Regional Manager, Southern Europe
SomaLogic, Ltd.
nautret@somalogic.com

Abstract

Even though proteins are the targets of 95% of all known drugs, and downstream of both genetics and the environment, proteomics has failed to generate even a fraction of the excitement that drives the genomics revolution. This has been justifiable until now because large scale, high throughput, highly multiplexed protein measurements have not been possible.

With the availability of the SOMAscan 1.3k assay, using modified DNA-based reagents which form highly specific complexes with proteins, we have re-purposed genetic technologies to measure proteins at unprecedented scale and performance: sub-picogram detection of thousands of proteins with high precision and tiny volumes of sample.

Examples from cancer, neurological disorders up to cardiovascular diseases will be shown of how the individual novel reagents as well as the SOMAscan assay are being used to uncover new biology, validate new targets and deliver actionable information for medical practice and drug development.